藍帆醫療(002382.SZ):藍帆柏盛擬繼續引入A2輪戰略投資者大興臨空發展基金進行增資擴股
格隆匯5月20日丨藍帆醫療(002382.SZ)公佈,結合藍帆柏盛自身發展需要和資本運作規劃的綜合考慮,並根據《A1輪投資協議》約定的後續融資安排,藍帆柏盛擬繼續引入A2輪戰略投資者大興臨空發展基金進行增資擴股,本次投資方擬按照49億元的投前估值以現金方式向藍帆柏盛增資金額合計人民幣1億元,認購藍帆柏盛新增註冊資本254.8279萬元,對應本次交易後藍帆柏盛全部股權的2.0000%。
公司、公司全資子公司NVTHK及A1輪投資方放棄本次增資的優先認購權。本次增資完成後,藍帆柏盛的註冊資本將由12,486.5671萬元人民幣增加至12,741.3950萬元人民幣,公司持有藍帆柏盛的股權比例將由81.6327%變更為80.0000%,藍帆柏盛仍然是公司控股子公司,將繼續納入公司合併報表範圍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.